Anemia Treatment Market Report by Disease Type, Therapy Class, Route of Administration, Countries and Company Analysis, 2025-2033

Global Anemia Treatment Market Analysis (2025-2033)

The treatment market for anemia around the world is set to see significant growth, from US$ 11.84 billion in 2024 to US$ 22.45 billion by 2033. This is due to rising awareness of the effects of anemia and improved treatment measures. The market is set to grow at a compound annual growth rate (CAGR) of 7.37% between 2025 and 2033 based on innovations and better patient care measures.

Global Anemia Treatment Market Report by Disease Type (Iron Deficiency Anemia, CKD Anemia, Sickle Cell Anemia, Aplastic Anemia, Thalassemia, Other Rare Anemias), Therapy Class (Oral Iron Supplements, Intravenous Iron, ESAs, Iron Chelators, HIF-PH Inhibitors, Others), Route of Administration (Oral, Injectable), Countries and Company Analysis, 2025-2033.

Global Anemia Treatment Market Outlook

Treatment of anemia involves dealing with the underlying cause of the disease, which is a deficiency in healthy red blood cells to transport sufficient oxygen to the tissues in the body. Diet modification, iron tablets, vitamin B12 injections, and drugs such as erythropoietin that stimulate the production of red blood cells are the typical treatments. Severe anemia can result in the need for blood transfusion or bone marrow transplantation.

Treatment regimen commonly relies upon the type of anemia-iron-deficiency anemia being the most prevalent. As anemia awareness increases, so does interest in treatments to enhance energy and overall well-being.

Moreover, with increasing emphasis on preventive care, many individuals are seeking preventive supplementation and lifestyle adjustments, enhancing the treatment's popularity. Healthcare providers often recommend routine screenings, especially for at-risk populations such as women, pregnant individuals, and those with chronic diseases. Overall, effective anemia treatment significantly impacts quality of life, making it a crucial area in healthcare.

Growth Drivers in the Global Anemia Treatment Market

Rising Prevalence of Anemia Worldwide

An expanding global burden of anemia, specifically in women of childbearing age, children, and the elderly, is a major push for the anemia treatment market. Over 1.6 billion individuals worldwide are affected by anemia, and the leading cause of anemia is iron deficiency, as reported by WHO. An expanding number of cases associated with chronic conditions, nutritional deficiencies, and genetic disorders such as thalassemia and sickle cell anemia are spurring demand for treatments. The burden is especially high in developing regions, where poor nutrition and limited healthcare access worsen prevalence. This rising patient pool continues to create sustained demand for anemia therapies globally. The WHO Regions of Africa and South-East Asia are most affected with an estimated 106 million women and 103 million children affected by anaemia in Africa and 244 million women and 83 million children affected in South-East Asia.

Technological Innovations in Treatment Methodologies

The market for the treatment of anemia is growing rapidly owing to innovations in drug formulations, delivery systems, and new therapeutic modalities. Innovative therapies like intravenous (IV) iron formulations, erythropoiesis-stimulating agents (ESAs), and gene therapy for anemic disorders are enhancing patient outcomes. Advanced therapies minimize side effects, enhance efficacy, and provide convenient dosing frequencies. In addition, drug development by biotechnology is offering targeted treatments for certain forms of anemia, such as anemia associated with CKD and cancer. With ongoing innovation, enhanced availability to innovative treatments is fueling the global market's growth. August 2023, Bristol Myers Squibb (NYSE: BMY) reported that the FDA has approved Reblozyl(R) (luspatercept-aamt) for the treatment of anemia in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who are ESA-naive and might require frequent RBC transfusions. This first-line clearance is on the basis of interim Phase 3 COMMANDS trial results, which reported that Reblozyl offers higher efficacy in RBC transfusion independence and hemoglobin rise over epoetin alfa in both ring sideroblast-positive and ring sideroblast-negative patients. This reflects Reblozyl's potential to treat chronic anemia earlier for more patients.

Boosting Healthcare Investments and Awareness

Growing healthcare spending and increased awareness about the health consequences of anemia are strong market drivers. Governments and healthcare institutions across the globe are launching awareness campaigns and nutritional initiatives to meet iron deficiency anemia. Public-private collaborations are financing affordable access to treatment, especially in emerging economies. And growth in diagnostic tests is facilitating early diagnosis, enhancing treatment uptake. Drug makers are also increasing outreach in underserved areas to reach untapped demand. Stronger investments in healthcare infrastructure and education have led to increased access to anemia treatments, and the success pattern of this market is reflected in the growth curve. June 2024, Geron Corporation said that the FDA has approved RYTELO(TM) (imetelstat) for adult patients with lower-risk or intermediate-1 risk myelodysplastic syndromes, who have transfusion-dependent anemia and have not responded to erythropoiesis-stimulating agents.

Global Anemia Treatment Market Challenges

High Rate of Treatment and Poor Accessibility

One of the main challenges to the market of anemia treatments is that expensive advanced therapies, such as ESAs and intravenous iron products, are quite costly. In middle- and low-income nations, limited healthcare infrastructure and affordability limit patient access to quality treatments. Some patients use inexpensive oral iron supplements, which are not adequate for more serious cases. Lack of reimbursement policies in certain areas also decreases access to advanced therapies. This inconsistency between low-income and high-income countries results in an imbalanced market environment, limiting the aggregate growth potential of the anemia treatment market.

Side Effects and Safety Issues of Treatments

Anemia treatments are necessary but come with dangers and side effects that limit their mass appeal. Oral iron supplements can produce gastrointestinal side effects, while intravenous iron risks causing allergic reactions. ESAs, while being effective, carry cardiovascular risks and could potentially be unsuitable for patients. They are often non-compliant due to these safety issues, diminishing the efficacy of treatment. Additionally, chronic treatment of genetic anemias such as thalassemia includes frequent transfusions that can increase iron overload and complications. These issues are a primary concern for better patient compliance and market growth.

CKD Anemia Treatment Market

CKD-associated anemia is one of the largest segments in the global market for anemia treatment. CKD patients tend to develop anemia because the injured kidneys are unable to produce enough erythropoietin. Therapy usually involves erythropoiesis-stimulating agents (ESAs), iron, and, in desperate situations, blood transfusions. Increasing prevalence of CKD across the world, mainly caused by diabetes and hypertension, is contributing substantially to demand for CKD anemia therapies. Pharmaceutical breakthroughs like hypoxia-inducible factor (HIF) stabilizers are also showing great potential as alternatives to conventional therapy. As cases of CKD increase and there is increasing awareness of its association with anemia, this segment of the market is growing at a phenomenal rate.

Aplastic Anemia Treatment Market

The market for aplastic anemia treatment is concentrated on the condition of rare but severe bone marrow failure with decreased blood cell production. Treatment involves immunosuppressive therapy, blood transfusion, and bone marrow transplantation for selected patients. Stem cell transplant and targeted therapy advances are enhancing survival and outcomes. Despite its rarity, growing diagnosis and access to advanced treatment are spurring market growth. Donor availability issues and associated high treatment costs remain hurdles, especially in developing areas. However, ongoing research into new therapeutics is likely to further reinforce this niche market segment.

Intravenous Iron Anemia Treatment Market

The intravenous (IV) iron treatment segment is expanding highly because of its efficiency in treating moderate and severe iron deficiency anemia, particularly among patients who are intolerant to oral iron. IV iron offers quicker restoration of iron stores and better outcomes, especially among patients with CKD, cancer, and postpartum anemia. Technological improvements have created safer products with lower side effects, leading to increased adoption. Increased hospital utilization of IV iron in perioperative care is another factor favoring market growth. While increased expense relative to oral supplementation is a problem, the greater efficacy and shorter duration of treatment make IV iron a clinical choice.

Iron Chelators Anemia Treatment Market

The iron chelators market segment serves patients suffering from iron overload as a consequence of frequent blood transfusions, which are prevalent in thalassemia, sickle cell anemia, and aplastic anemia. Iron chelators like deferoxamine, deferasirox, and deferiprone facilitate removal of excess iron, thereby decreasing the chances of organ damage. Increasing prevalence of transfusion-dependent anemias is fueling demand for these treatments. The oral formulations show better compliance than the older injectable versions. Nevertheless, expense and side effects in the form of gastrointestinal disturbances and renal toxicity restrict wider use. Ongoing innovation on safer and less expensive iron chelators will underpin future growth in the market.

Oral Anemia Treatment Market

Oral iron agents are still the most common treatment for anemia owing to their accessibility, affordability, and simplicity of administration. They are usually used for mild to moderate iron deficiency anemia, particularly in women and children. The segment enjoys strong demand in under-developed world regions with poor healthcare access. Nevertheless, gastrointestinal side effects and lower absorption levels than IV iron restrict their use in severe cases. Oral treatments, however, suffer from these disadvantages and are a market leader due to cost-effectiveness and availability, thus forming a key part of anemia control measures across the world.

United States Anemia Treatment Market

The American anemia treatment market is fueled by growing incidence of CKD, anemia induced by cancer, and nutritional deficiencies. Robust healthcare infrastructure, extensive awareness, and availability of sophisticated treatments like ESAs and IV iron favor growth. The nation also tops research and development, propelling innovation in new therapeutics such as HIF stabilizers and gene therapy. Access problems with insurance and steep treatment expenses are issues. With an abundant patient population, advanced therapies, and strong presence of industry, the U.S. is one of the most profitable markets for anemia treatment in the world. Feb 2024, FDA has approved Pyrukynd (mitapivat) tablets for treatment of adults with hemolytic anemia owing to pyruvate kinase deficiency.

Germany Anemia Treatment Market

Germany's anemia treatment market is supported by a well-developed healthcare system and high emphasis on early detection. High incidence of iron deficiency anemia, particularly among women and older populations, fuels treatment demand. Strong uptake of innovative treatments, such as IV iron products and ESAs, is supported by reimbursement policies in the country. Increasing demand for nutritional foods and supplements also augments curative treatments. But high-regulatory standards can be a hindrance for the introduction of new treatments. Germany, with its developed infrastructure and focus on quality healthcare, continues to be a major player in Europe's market for the treatment of anemia. September 2024, PharmaNutra S.p.a. reported entering into an agreement with Fresenius Kabi to distribute their SiderAL Forte 30 mg and SiderAL 14 mg in Germany. These are iron-based drugs that are produced with Sucrosomal Technology. The technology is an innovative and patented technology of PharmaNutra that enhances its absorption and tolerance.

India Anemia Treatment Market

India's anemia treatment market is growing at a fast pace as a result of the high prevalence of anemia in the country, especially among women and children. Government initiatives such as the Anemia Mukt Bharat program are promoting awareness and uptake of treatment. Oral iron supplements have the highest market share because they are cheap and easily accessible. But growing availability of IV iron therapies and nutritional interventions is enhancing outcomes for critical cases. Inadequate healthcare infrastructure and unaffordability in rural areas limit access to high-end treatments. Despite these limitations, India is a high-growth market because of a large patient population and government favoritism. JULY 2023, The government is determined to eradicate the disease prior to India's Amrit Kaal in 2047." This was remarked by the Hon'ble Prime Minister of India inaugurated the National Sickle Cell Anaemia Elimination Mission (NSCEM) at Shahdol, Madhya Pradesh.

Brazil Anemia Treatment Market

The anemia treatment market in Brazil is expanding steadily fueled by high incidence of nutritional anemia and rising cases attributed to chronic diseases. Public health programs encouraging food fortification and iron supplementation are driving market expansion. The nation also displays increasing hospital adoption of IV iron treatments for critical anemia cases. Economic fluctuations, however, and the uneven delivery of healthcare in rural areas restrict uniform treatment adoption. Public-private alliances are enhancing access. With increased healthcare consciousness and investment in infrastructure, Brazil's anemia treatment market will develop robustly over the next few years. June 2023, Medicines for Malaria Venture (MMV) and PATH announced that Brazil became the first malaria-endemic country to include the STANDARD(TM) G6PD Test and single-dose tafenoquine in its public health system for the radical cure of Plasmodium vivax (P. vivax) malaria, providing a straightforward and effective radical cure to avert relapses.

Saudi Arabia Anemia Treatment Market

The anemia treatment market in Saudi Arabia is growing because of a high prevalence of genetic diseases like thalassemia and sickle cell anemia, as well as nutritional deficiencies. The government's strong support for healthcare under Vision 2030, combined with investment in sophisticated treatment centers, is driving market growth. Oral and intravenous iron treatments are common, while genetic analysis and newer treatments are increasingly popular for inherited anemias. Nonetheless, cultural reasons and lack of awareness in rural regions might limit early detection. With the increasing needs for contemporary health care and government emphasis on orphan diseases, Saudi Arabia is increasingly becoming a significant market in the Middle East. Aug 2025, Agios Pharmaceuticals, Inc. revealed that the Saudi Food and Drug Authority approved PYRUKYND(R) (mitapivat) for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.

Market Segmentation

Disease Type

• Iron Deficiency Anemia
• CKD Anemia
• Sickle Cell Anemia
• Aplastic Anemia
• Thalassemia
• Other Rare Anemias

Therapy Class

• Oral Iron Supplements
• Intravenous Iron
• ESAs
• Iron Chelators
• HIF-PH Inhibitors
• Others

Route of Administration

• Oral
• Injectable

Country

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• South Korea
• Thailand
• Malaysia
• Indonesia
• Australia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• Saudi Arabia
• UAE
• South Africa

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

1. Akebia Therapeutics

2. GSK plc

3. Vertex Pharmaceuticals

4. Pfizer

5. Sanofi

6. Takeda

7. Novartis

8. Johnson & Johnson

9. Roche

10. Biocon Biologics